Radiographic patterns of progression in patients with EGFR-mutant NSCLC undergoing EGFR TKI therapy.

被引：0
|
作者：
Brenner, Nicole [1 ]
Bastos, Bruno R. [1 ]
机构：
[1] Cleveland Clin Florida, Weston, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19108
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Treatment Patterns and Clinical Outcomes in Patients with EGFR-mutant NSCLC after Progression on First-Line Osimertinib
    Robinson, N. D.
    Zhan, P.
    Udelsman, B.
    Boffa, D. J.
    Goldberg, S. B.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S364 - S364
  • [32] Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib
    Nishino, Mizuki
    Dahlberg, Suzanne E.
    Fulton, Linnea E.
    Digumarthy, Subba R.
    Hatabu, Hiroto
    Johnson, Bruce E.
    Sequist, Lecia V.
    [J]. ACADEMIC RADIOLOGY, 2016, 23 (03) : 329 - 336
  • [33] Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
    Ju J.-S.
    Huang A.C.-C.
    Tung P.-H.
    Huang C.-H.
    Chiu T.-H.
    Wang C.-C.
    Ko H.-W.
    Chung F.-T.
    Hsu P.-C.
    Fang Y.-F.
    Guo Y.-K.
    Kuo C.-H.S.
    Yang C.-T.
    [J]. Scientific Reports, 13 (1)
  • [34] Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis
    Qian, Xiaoyu
    Guo, Xiaodan
    Li, Ting
    Hu, Wei
    Zhang, Lin
    Wu, Caisheng
    Ye, Feng
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [35] First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease
    Xu, Qinghua
    Liu, Hui
    Meng, Shuyan
    Jiang, Tao
    Li, Xuefei
    Liang, Shixiong
    Ren, Shengxiang
    Zhou, Caicun
    [J]. JOURNAL OF CANCER, 2019, 10 (02): : 522 - 529
  • [36] Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI
    Chang, John Wen-Cheng
    Huang, Chen-Yang
    Fang, Yueh-Fu
    Chang, Ching-Fu
    Yang, Cheng-Ta
    Kuo, Chih-Hsi Scott
    Hsu, Ping-Chih
    Wu, Chiao-En
    [J]. CANCERS, 2022, 14 (04)
  • [37] The Difference in Clinical Outcomes Between Osimertinib and EGFR-TKI plus Anti-angiogenic Agent in EGFR-mutant NSCLC Patients
    Huang, Y. H.
    Hsu, K. -H.
    Tseng, J. -S.
    Chen, K. -C.
    Chang, G. -C.
    Yang, T. -Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S477 - S478
  • [38] Concurrent Brain Radiotherapy and EGFR-TKI Have Better Survival Benefits in Patients with Brain Metastases from EGFR-Mutant NSCLC
    Zhu, Y.
    Chen, Y.
    Han, S.
    Ying, X.
    Sun, X.
    Xu, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S502 - S502
  • [39] Osimertinib plus selumetinib for patients (pts) with EGFR-mutant (EGFRm) NSCLC following disease progression on an EGFR-TKI: Results from the Phase Ib TATTON study
    Ramalingam, Suresh S.
    Saka, Hideo
    Ahn, Myung-Ju
    Yu, Helena
    Horn, Leora
    Hida, Toyoaki
    Cantarini, Mireille
    Verheijen, Remy
    Wessen, Jonathan
    Oxnard, Geoffrey
    Ohe, Yuichiro
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [40] ILLUMINATE: Efficacy and Safety of Durvalumab/ Tremelimumab and Chemotherapy in EGFR-Mutant NSCLC Following Progression on EGFR Inhibitors
    不详
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (10) : 8 - 9
12345